Heim500124 • BOM
add
Dr Reddy's Laboratories Ltd
Við síðustu lokun
1.200,50 ₹
Dagbil
1.188,65 ₹ - 1.210,40 ₹
Árabil
1.074,35 ₹ - 1.420,20 ₹
Markaðsvirði
993,03 ma. INR
Meðalmagn
58,81 þ.
V/H-hlutf.
18,61
A/V-hlutfall
0,67%
Aðalkauphöll
NSE
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(INR) | sep. 2024info | Breyting á/á |
---|---|---|
Tekjur | 80,16 ma. | 16,51% |
Rekstrarkostnaður | 29,72 ma. | 24,54% |
Nettótekjur | 12,55 ma. | -15,18% |
Hagnaðarhlutfall | 15,66 | -27,20% |
Hagnaður á hvern hlut | 15,83 | -11,13% |
EBITDA | 22,02 ma. | 8,53% |
Virkt skatthlutfall | 30,01% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
(INR) | sep. 2024info | Breyting á/á |
---|---|---|
Reiðufé og skammtímafjárfestingar | 63,07 ma. | -7,15% |
Heildareignir | 465,96 ma. | 34,27% |
Heildarskuldir | 156,67 ma. | 66,79% |
Eigið fé alls | 309,28 ma. | — |
Útistandandi hlutabréf | 833,05 m. | — |
Eiginfjárgengi | 3,28 | — |
Arðsemi eigna | 10,24% | — |
Ávöxtun eigin fjár | 13,21% | — |
Peningaflæði
Breyting á handbæru fé
(INR) | sep. 2024info | Breyting á/á |
---|---|---|
Nettótekjur | 12,55 ma. | -15,18% |
Handbært fé frá rekstri | 9,32 ma. | -48,03% |
Reiðufé frá fjárfestingum | -19,07 ma. | -322,21% |
Reiðufé frá fjármögnun | 16,15 ma. | 329,53% |
Breyting á handbæru fé | 6,37 ma. | 1,03% |
Frjálst peningaflæði | 3,92 ma. | -72,47% |
Um
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Framkvæmdastjóri
Stofnsett
1984
Höfuðstöðvar
Vefsvæði
Starfsfólk
27.048